Back to Search
Start Over
Ultragenyx says Phase 3 study of Crysvita met primary endpoint
- Source :
- The Fly. May 17, 2018
- Publication Year :
- 2018
-
Abstract
- Ultragenyx Pharmaceutical announced that the Phase 3 study of Crysvita met its primary endpoint demonstrating that Crysvita was superior to oral phosphate and active vitamin D in improving rickets in [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.539102037